ArthroCare Sews Up an Advantage in Sports Medicine

In a rapidly growing market like the sports medicine segment of orthopedics, it pays for companies to strike early. The introduction of new technologies and a population that alternates between sedentary work weeks and extreme sports on the weekends are fueling market growth rates of 30% annually. Thus, ArthroCare Corp. didn't hesitate to snap up five-year-old Opus Medical Inc., developer of a novel suturing and anchor system for arthroscopic soft tissue repair. In sports medicine, AthroCare's largest and most established target market (spine and ear, nose & throat are its other major markets), the Opus technology will help ArthroCare increase market penetration.

In a rapidly growing market like the sports medicine segment of orthopedics, it pays for companies to strike early. The introduction of new technologies and a population that alternates between sedentary work weeks and extreme sports on the weekends are fueling market growth rates of 30% annually. The American Association of Orthopedic Surgeons estimates that approximately 11% of all injuries—things like fractures, dislocations, and tears to the knees and shoulders--are related to sports, to the tune of 6.6 million such injuries each year. Three-quarters of these patients are under the age of 65. An increase in the number of aging and active people is bound to contribute to the growing number of injuries. Thus, ArthroCare Corp. didn't hesitate to snap up five-year-old Opus Medical Inc. for $130 million in a combination of cash and stock, plus earn-outs based on sales thresholds. [See Deal] Indeed, says ArthroCare president Michael Baker, the company has been in discussions with Opus for a year.

Opus was founded in 1999 by venture firms Three Arch Partners and Prospect Venture Partners to develop AutoCuff, a system...

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.